Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wade you think too much. There is no issue with EBITDA. Small caps getting hammered.
STXS great timing. Sir John Templetomns fund buys 20% stake
STXS- Thankfully, in the investment world, the past is irrelevant to someone considering a prospective investment.
Thats why I have been accumulating and now own 2.5% of the company at these insane prices.
STXS:NASDAQ $1.28 7 MM float Medical robotics
Medical robotics is one of the hottest fields. HNSN and STXS historically traded at over $100 MM market caps.
After doing a reverse split STXS has been pouunded down to an insane $9 MM market cap even though it is posied to achieve positive cash flow and earnings in 2013 for the first time ever.
-Agressive cost cuts have reduced breakeven point.
-The company just confirmed business is accelerating. With the upturn in business and cost cuts, STXS should be cash flow positive by year end.
-Just completed debt financing with venture fund convertible at $3.30 per share.
-The potential upside here is significant.
If HNSN recently had a $100 MM market cap with tons of losses, what kind of value can STXS achieve with profitability?
STXS IS NOW IN ITS BEST SHAPE IN HISTORY, TRADING AT A PRE SPLIT PRICE OF 12 CENTS. These insane prices will soon be a thing of the past wnen tax loss selling ends.
STXS:NASDAQ $1.28 7 MM float Medical robotics 10 bagger potential
Medical robotics is one of the hottest fields. HNSN and STXShistorically traded at over $100 MM market caps.
After doing a reverse split STXS has been pouunded down to an insane $9 MM market cap even though it is posied to achieve positive cash flow and earnings in 2013 for the first time ever.
-Agressive cost cuts have reduced breakeven point.
-The company just confirmed business is accelerating. With the upturn in business and cost cuts, STXS should be cash flow positive by year end.
-Just completed financing with venture fund with debt convertible at $3.30 per share.
The potential upside here is significant.. If HNSN recently had a $100 MM market cap with tons of losses, what kind of value can STXS achieve with profitability?
There is a reason the venture fund provided STXS $18 million convertible at $3.30.
STXS IS NOW IN ITS BEST SHAPE IN HISTORY, TRADING AT A PRE SPLIT PRICE OF 12 CENTS. These insane prices will soon be a thing of the past wne tax loss selling ends.
FFEX:NASDAQ $1.86: $.15 Q3 EPS next week
FFEX announced $.06 EPS in Q4 2011, AND IS PROJECTED TO EARN AT LEAST $.26 PER SHARE IN THE SECOND HALF OF 2012 BASED ON GUIDANCE (CEO Said full year profit after loss of $.26 EPS in first half)
-FFEX trades at a P/S ratio of 0.07 compared to the Industry average of 0.62 If FFEX traded at even HALF the sector average it would be $5.
FFEX has slashed costs to the bone by investing in fuel efficient trucks. They are growing revenues and more importantly, MARGINS, by diversifying into bulk water transportation for the crude oil sector.
FFEX has a tightly held 11 Million float. FFEX traded at $10 in 2007. The results projected for the second half of 2012 will surpass the 2007 results.
In short, FFEX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
-Profitable
-11 MM share float
-$25 MM market cap
-$380 MM + revenues
-Will earn at least $.26 EPS in second hald of 2012 based on CEO guidance.
-Traded at $10+ in 2007
-Frequently mentioned as acquisition candidate because of heavy industry consolidion
-Diversification into water trucking business for oil sector substantially improving sales and margins and provides huge growth opportunity
Dude, one thing I have learned is people have short memories, in the stock market, in life in genera.
PPHM will be back.
If you can show me one other biotech trading ar cash value with pending Phase 3 I am all ears.
Bounce play AEZS: $50 MM cash, $58 MM Market cap, Huge Phase 3 results soon
Q1 2013
AEZS expects to reach the Interim Analysis of Perifosine's Phase 3 clinical trial for Relapsed and Refractory Multiple Myeloma. The trial began in December of 2009, and AEZS decided to move ahead with this trial after it received the rights of Perifosine back from Keryx earlier this year, based on the strength of the Phase I/II trial results. The full trial is expected to be approximately 400 patients in 10 countries, including 40 to 50 sites in the U.S. The primary endpoint of the trial is progression free survival, with secondary endpoints of overall survival, overall response rate and safety. About 265 events, categorized as disease progression or death, will trigger data to be unblinded.
The Interim Analysis of safety, efficacy and futility is scheduled after 80 events. The management expects this threshold to occur in the first quarter of 2013. If positive activity trends are identified, the trial can continue to add patients. If this occurs, the stock should have a positive reaction.
On Tuesday, analysts at Maxim sent clients an initiation report covering AEterna Zentaris with a BUY recommendation and a $9 price target for recently discounted shares. Given the historical data and the current design and execution of the phase III trial in multiple myeloma, the banking firm's research team believes perifosine has a strong probability of meeting its SPA-approved primary endpoint. The analyst wrote:
"We are initiating coverage of AEterna Zentaris with a Buy rating and a 12-month price target of $9.00. We believe that Aeterna Zentaris is misunderstood as a result of the failed trial that partner Keryx (KERX-$2.78.NR) experienced with perifosine in colon cancer (the "X-PECT" trial). Data from phase I/II trials in multiple myeloma (MM) suggest that perifosine is an active molecule in this hematological malignancy. It is not uncommon in the cancer research paradigm to see a compound fail in one trial and then succeed in another when dosing and other parameters are varied, as was the case with Avastin (by Roche-RHHBY, $49.41, NR) and Nexavar (by Onyx-ONXX, $89.70, NR). "
AEZS: $50 MM cash, $58 MM Market cap, Huge Phase 3 results soon
Q1 2013
AEZS expects to reach the Interim Analysis of Perifosine's Phase 3 clinical trial for Relapsed and Refractory Multiple Myeloma. The trial began in December of 2009, and AEZS decided to move ahead with this trial after it received the rights of Perifosine back from Keryx earlier this year, based on the strength of the Phase I/II trial results. The full trial is expected to be approximately 400 patients in 10 countries, including 40 to 50 sites in the U.S. The primary endpoint of the trial is progression free survival, with secondary endpoints of overall survival, overall response rate and safety. About 265 events, categorized as disease progression or death, will trigger data to be unblinded.
The Interim Analysis of safety, efficacy and futility is scheduled after 80 events. The management expects this threshold to occur in the first quarter of 2013. If positive activity trends are identified, the trial can continue to add patients. If this occurs, the stock should have a positive reaction.
On Tuesday, analysts at Maxim sent clients an initiation report covering AEterna Zentaris with a BUY recommendation and a $9 price target for recently discounted shares. Given the historical data and the current design and execution of the phase III trial in multiple myeloma, the banking firm's research team believes perifosine has a strong probability of meeting its SPA-approved primary endpoint. The analyst wrote:
"We are initiating coverage of AEterna Zentaris with a Buy rating and a 12-month price target of $9.00. We believe that Aeterna Zentaris is misunderstood as a result of the failed trial that partner Keryx (KERX-$2.78.NR) experienced with perifosine in colon cancer (the "X-PECT" trial). Data from phase I/II trials in multiple myeloma (MM) suggest that perifosine is an active molecule in this hematological malignancy. It is not uncommon in the cancer research paradigm to see a compound fail in one trial and then succeed in another when dosing and other parameters are varied, as was the case with Avastin (by Roche-RHHBY, $49.41, NR) and Nexavar (by Onyx-ONXX, $89.70, NR). "
AEZS: $50 MM cash, $58 MM Market cap, Phase 3 results soon
Q1 2013
AEZS expects to reach the Interim Analysis of Perifosine's Phase 3 clinical trial for Relapsed and Refractory Multiple Myeloma. The trial began in December of 2009, and AEZS decided to move ahead with this trial after it received the rights of Perifosine back from Keryx earlier this year, based on the strength of the Phase I/II trial results. The full trial is expected to be approximately 400 patients in 10 countries, including 40 to 50 sites in the U.S. The primary endpoint of the trial is progression free survival, with secondary endpoints of overall survival, overall response rate and safety. About 265 events, categorized as disease progression or death, will trigger data to be unblinded.
The Interim Analysis of safety, efficacy and futility is scheduled after 80 events. The management expects this threshold to occur in the first quarter of 2013. If positive activity trends are identified, the trial can continue to add patients. If this occurs, the stock should have a positive reaction.
On Tuesday, analysts at Maxim sent clients an initiation report covering AEterna Zentaris with a BUY recommendation and a $9 price target for recently discounted shares. Given the historical data and the current design and execution of the phase III trial in multiple myeloma, the banking firm's research team believes perifosine has a strong probability of meeting its SPA-approved primary endpoint. The analyst wrote:
"We are initiating coverage of AEterna Zentaris with a Buy rating and a 12-month price target of $9.00. We believe that Aeterna Zentaris is misunderstood as a result of the failed trial that partner Keryx (KERX-$2.78.NR) experienced with perifosine in colon cancer (the "X-PECT" trial). Data from phase I/II trials in multiple myeloma (MM) suggest that perifosine is an active molecule in this hematological malignancy. It is not uncommon in the cancer research paradigm to see a compound fail in one trial and then succeed in another when dosing and other parameters are varied, as was the case with Avastin (by Roche-RHHBY, $49.41, NR) and Nexavar (by Onyx-ONXX, $89.70, NR). "
APPY +30% to $2.75 7 MM float launching Appendicitis test $1 Billion Market
APPY rose 30% last week to $2.75, but is just starting.
APPY has the potential to rise to $10 + very quickly like ROSG and RPRX:
-7 Million float
-$1.3 per share cash
APPY IS LAUNCHING A PROVEN APPENDICITIS TEST WITH A $1 BILLION WORLD WIDE POTENTIAL MARKET IN EUROPE THIS YEAR, U.S. LAUNCH IN 2013.
The following highlights the market potential of the test:
What is the size of the market for the product?
Over 9 million patients present annually to ERs in the US with abdominal pain. This is the single largest reason for ER visits. We believe that approximately 6 million of these patients would be candidates for our blood test. We have not finalized pricing for the test but we believe pricing will be in the $100 range. When we take into account the international opportunity, we believe the global market size to be in the $1 billion range. QUESTION- What is the status of the product? Answer- In 2011 we completed a 503 patient study across 11 hospitals in the United States. The performance was excellent; the test performed at a negative predictive value (NPV) of 97%. Clinicians have indicated that they would be highly motivated to order a test that performs at this level. Our next step in the US is to complete an FDA pivotal trial which is scheduled to start in Q3 of 2012 and finish in Q1 of 2013. The FDA trial will be very similar in design to the study we completed in 2011. We plan to launch in Europe in Q4 of 2012; there is no requirement for an FDA pivotal trial for European launch
APPY 7 MM float + 30% to $2.75, could go to $10 IMO
APPY could be next RPRX or ROSG
- 7 MM float
-Proven appendicitis test with $1 BIllion potential market
-Will market in Europe later this year, US approval likely in 2013
Over 9 million patients present annually to ERs in the US with abdominal pain. This is the single largest reason for ER visits. We believe that approximately 6 million of these patients would be candidates for our blood test. We have not finalized pricing for the test but we believe pricing will be in the $100 range. When we take into account the international opportunity, we believe the global market size to be in the $1 billion range. QUESTION- What is the status of the product? Answer- In 2011 we completed a 503 patient study across 11 hospitals in the United States. The performance was excellent; the test performed at a negative predictive value (NPV) of 97%. Clinicians have indicated that they would be highly motivated to order a test that performs at this level. Our next step in the US is to complete an FDA pivotal trial which is scheduled to start in Q3 of 2012 and finish in Q1 of 2013. The FDA trial will be very similar in design to the study we completed in 2011. We plan to launch in Europe in Q4 of 2012; there is no requirement for an FDA pivotal trial for European launch
APPY up 30% to $2.50 7 MM float, Appenicitis test approval in Q4, HUGE market.
The numbers just U.S.6 Million ER visits with Appendicitous symptoms, 700,000 surgeries,
100,000 surgeries unnecessary, 100,000 sent home who later come back with a burst appendix, MRI current diagnostic, costs thousands, exposes to lots of radiation. Given the prevalence of and consequences of an incorrect diagnosis, ER docs will be crazy not to perform this test on the blood they already have. The financial numbers : tests 2 Million to 5 Million, cost $100 to $500.
FFEX:NASDAQ 4 forward PE frac water transport
FFEX is up signifcantly since Q2 earnings, but is still trading at a huge discount.
FFEX announced $.06 EPS in Q4 2012, AND IS PROJECTED TO EARN AT LEAST $.26 PER SHARE IN THE SECOND HALF OF 2012 BASED ON THE FOLLOWING GUIDANCE FROM THE CEO:
-The Company expects that quarterly results will continue to improve throughout the year.
-We are on track to restore the Company to profitability this year.
-FFEX trades at a P/S ratio of 0.07 compared to the Industry average of 0.62 If FFEX traded at even HALF the sector average it would be $5.
FFEX has slashed costs to the bone by investing in fuel efficient trucks. They are growing revenues and more importantly, MARGINS, by diversifying into bulk water transportation for the crude oil sector.
FFEX has a tightly held 11 Million float.
FFEX traded at $10 in 2007. The results projected for the second half of 2012 will surpass the 2007 results.
In short, FFEX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 11 MM share float
- $25 MM market cap
- $380 MM + revenues
- Will earn at least $.26 EPS in second hald of 2012 based on CEO guidance.
- Traded at $10+ in 2007
- Frequently mentioned as acquisition candidate because of heavy industry consolidion
- Diversification into water trucking business for oil sector substantially improving sales and margins and provides huge growth opportunity
Rating :
(No ratings)
panalta2000
51/Male
Edmonton, A...
View Messages
Rep
FFEX:NASDAQ $1.6 3 forward PE
FFEX is up signifcantly since Q2 earnings, but is still trading at a huge discount.
FFEX announced $.06 EPS in Q4 2009, AND IS PROJECTED TO EARN AT LEAST $.26 PER SHARE IN THE SECOND HALF OF 2012 BASED ON THE FOLLOWING GUIDANCE FROM THE CEO:
-The Company expects that quarterly results will continue to improve throughout the year.
-We are on track to restore the Company to profitability this year.
-FFEX trades at a P/S ratio of 0.07 compared to the Industry average of 0.62 If FFEX traded at even HALF the sector average it would be $5.
FFEX has slashed costs to the bone by investing in fuel efficient trucks. They are growing revenues and more importantly, MARGINS, by diversifying into bulk water transportation for the crude oil sector.
FFEX has a tightly held 11 Million float.
FFEX traded at $10 in 2007. The results projected for the second half of 2012 will surpass the 2007 results.
In short, FFEX has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable
- 11 MM share float
- $25 MM market cap
- $380 MM + revenues
- Will earn at least $.26 EPS in second hald of 2012 based on CEO guidance.
- Traded at $10+ in 2007
- Frequently mentioned as acquisition candidate because of heavy industry consolidion
- Diversification into water trucking business for oil sector substantially improving sales and margins and provides huge growth opportunity
Next ROSG? STXS + $.50 to $2.14, just starting
STXS develops, manufactures, and sells medical robotics, a huge growth Industry. STXS has a large, recurring revenue base.
2.5 MM float, 5.5 Million shares OS.
$10 Million market cap.
CEO projects positive EBITDA by 2013.
Just raised $18 million in debt convertible at $3.2 per share.
STXS historically traded at over a $100 million market cap.
STXS trades at a HUGE discount to others in the sector:
HNSN
$22 MM revenue
$109 Million market cap
STXS
$41 million revenue
$10 million market cap.
In short, STXS is a rare find: A company in a huge growth sector turning profitable trading at a huge discount to peers and historical valuations.
STXS + $.50 to $2.14, just starting
STXS develops, manufactures, and sells medical robotics, a huge growth Industry. STXS has a large, recurring revenue base.
2.5 MM float, 5.5 Million shares OS.
$10 Million market cap.
CEO projects positive EBITDA by 2013.
Just raised $18 million in debt convertible at $3.2 per share.
STXS historically traded at over a $100 million market cap.
STXS trades at a HUGE discount to others in the sector:
HNSN
$22 MM revenue
$109 Million market cap
STXS
$41 million revenue
$10 million market cap.
In short, STXS is a rare find: A company in a huge growth sector turning profitable trading at a huge discount to peers and historical valuations.
AEHR No brainer. 7 MM float, $1.29, guided for profit in second half 2012.
Last time AEHR was profitable it was over $5. Could be next FSII which went from $1 to 44 very quickly.
We enter fiscal 2013 on a good footing with our highest backlog in over three years," continued Erickson. "We expect to achieve a profit and become cash flow positive by the end of the 2012 calendar year. We continue to focus on growing our company, while managing our cost structure to ensure future profitability."
BMTI up 10% after hours on new submission
http://www.reuters.com/article/2012/07/09/us-biomimetictherapeutics-fda-bonegraft-idUSBRE8681BE20120709?feedType=RSS&feedName=globalMarketsNews&rpc=43
BMTI was $10 a year ago. Lots of upside IMO.
I think APRI will pull a LCAV like move and run to $5 by July on the FDA meeting Health Canada meetings. With a small float and a drug that has shown remarkable reults, I think it will move fast.
To the Company's knowledge, no product is currently approved to treat FSAD, a persistent or recurring inability to attain, or maintain adequate sexual excitement, causing personal distress. Estimates of the FSAD market size put it on par with erectile dysfunction in males, and possibly larger.,
Sunglass season. PSUN:NASDAQ $1.47 will be $2.50 - $3 very soon IMO
-Will be EBITDA positive next 2 quarters
- .11 Price / Sales ratio which is 1/8 of Industry average
-Heading into seasonally strongest quarter
-History of explosive moves this time of year
-Trading at fraction of 2007 prices in $30 range
-Slashing costs, raising margins, closing underperforming stores. Management doing all the right things.
-Channel checks (e.g. Facebook) very strong according to Seeking Alpha article.
PSUN will be $2.50 - $3 very soon IMO
-Will be EBITDA positive next 2 quarters
- .11 Price / Sales ratio which is 1/8 of Industry average
-Heading into seasonally strongest quarter
-History of explosive moves this time of year
-Trading at fraction of 2007 prices in $30 range
-Slashing costs, raising margins, closing underperforming stores. Management doing all the right things.
-Channel checks (e.g. Facebook) very strong according to Seeking Alpha article.
PSUN will be $2.50 - $3 very soon IMO
-Will be EBITDA positive next 2 quarters
- .11 Price / Sales ratio which is 1/8 of Industry average
-Heading into seasonally strongest quarter
-History of explosive moves this time of year
-Trading at fraction of 2007 prices in $30 range
-Slashing costs, raising margins, closing underperforming stores. Management doing all the right things.
-Channel checks (e.g. Facebook) very strong according to Seeking Alpha article.
ROSG 2 MM float. $4,000 per Cancer test, 1.2 Million potential patients.
ROSG:NASDAQ just got Medicare approval for cancer test. $4,000 per test.
In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview® mets and miRview® mets² test, 60,000 from miRview® squamous, 60,000 from miRview® meso, 54,000 from miRview® kidney and more than 1 million patients worldwide from miRview® lung.
VRML went from pennies to $35 in a few months a few years back on optimism for a similar test, ROSH has much smaller float.
ROSG could run a lot higher, 2 MM float, 4,000 per test and this --->>>> In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview® mets and miRview® mets² test, 60,000 from miRview® squamous, 60,000 from miRview® meso, 54,000 from miRview® kidney and more than 1 million patients worldwide from miRview® lung.
ASTC:NASDAQ no brainer 5 forward PE
http://finance.yahoo.com/news/astrotech-reports-third-quarter-2012-110000579.html
ASTC is a no brainer for following reasons
-Just reported $.05 EPS
-Strong earnings will continue due to high back log ($35 million) and reduced R + D expenses after releasing spectrometer product
-ASTC was above $3 in 2010 with much worse earnings.
-Spectrometer has uses at airports for detectinhg emisssions from bombs.
-Small float.
Yeah thats what they said abiut LCAV at $2 when I recommended it.
Don't over analyze. The market is never perfectly efficient thats how you make money.
EDAP: New treatment for prostate cancer gives 'perfect results' for nine in ten men:
EDAP is the most undervalued biotech I follow. 13 million shares OS trades at $1.88, positive cash flow and will file NDA later this yeat for revolutionary cancer treatment.
This was $10 a few years back on anticipation of US filing and now its almost here.
A new treatment for prostate cancer can rid the disease from nine in ten men without debilitating side effects, a study has found, leading to new hope for tens of thousands of men.
By Rebecca Smith, Medical Editor10:00PM BST 16 Apr 201211 Comments
http://www.telegraph.co.uk/health/health...
It is hoped the new treatment, which involves heating only the tumours with a highly focused ultrasound, will mean men can be treated without an overnight stay in hospital and avoiding the distressing side effects associated with current therapies.
A study has found that focal HIFU, high-intensity focused ultrasound, provides the 'perfect' outcome of no major side effects and free of cancer 12 months after treatment, in nine out of ten cases.
Traditional surgery or radiotherapy can only provide the perfect outcome in half of cases currently.
Experts have said the results are 'very encouraging' and were a 'paradigm' shift in treatment of the disease.
It is hoped that large scale trials can now begin so the treatment could be offered routinely on the NHS within five years.
The National Institute for Health and Clinical Excellence will say in new guidance next week that the treatment is safe and effective and larger scale trials should go ahead.
A larger trial is already recruiting patients and men interested in the treatment should speak to their cancer doctor or GP about being referrred, experts said.
Prostate cancer is the commonest cancer in men with more than 37,000 diagnoses each year approximately 10,000 deaths.
Current treatments include surgery to remove the whole prostate or radiotherapy. Both of which can effectively treat the cancer but often cause side effects such as incontinence and impotence.
However in many men prostate cancer will not progress to a life threatening disease meaning that radical treatment risks side effects unnecessarily. For this reason, research is now focused on reducing side effects.
Focal HIFU involves careful selection of tumours, as small as a grain of rice, within the prostate gland and targeting them with highly focused ultrasound to heat them and destroy them.
The advantage over previous HIFU and other treatments is that damage to surrounding tissue is minimised, meaning there are far fewer side effects.
In the study published in the journal Lancet Oncology, 41 men were treated with focal HIFU. After 12 months, none were incontinent and one in ten suffered impotence.
The majority, 95 per cent, were free of cancer after 12 months.
Dr Hashim Ahmed, who led the study at University College London Hospitals NHS Foundation Trust andUniversity College London, said: “This changes the paradigm. By focusing just on the areas of cancer we reduce the collateral damage to surrounding tissue.
"Our results are very encouraging. We’re optimistic that men diagnosed with prostate cancer may soon be able to undergo a day case surgical procedure, which can be safely repeated once or twice, to treat their condition with very few side-effects. That could mean a significant improvement in their quality of life.
No brainer alert GV:AMEX + 20% $1.18
GV is up 100% this year, but is still trading at a huge discount.
GV announced $.06 EPS in Q4 2011 on $11 million sales.
GV HAS THE POTENTIAL TO EARN $.30 IN 2012 BASED ON $55 MILLION PROJECTED SALES.
The CEO stated that work from other electric utilities will provide a good opportunity for further growth. The prospects for the electrical construction business are brighter today than at any time in recent history.
GV has a tightly held 19 Million float.
In short, GV has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable.
- 19 MM share float.
- $30 MM market cap
- Electrical construction backlog increased to $77.8 million at February 27, 2012 from $12.2 million at year end.
- Q4 2011: $.06 EPS on $11 million revenue.
- 2012 Forecast: Revenue projected to increase to $55 million. Profits should approach $.30 per share.
-Most successful US Hedge Fund, Renaissance, owns stake.
No brainer alert GV:AMEX + 20%
GV is up 100% this year, but is still trading at a huge discount.
GV announced $.06 EPS in Q4 2011 on $11 million sales.
GV HAS THE POTENTIAL TO EARN $.30 IN 2012 BASED ON $55 MILLION PROJECTED SALES.
The CEO stated that work from other electric utilities will provide a good opportunity for further growth. The prospects for the electrical construction business are brighter today than at any time in recent history.
GV has a tightly held 19 Million float.
In short, GV has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable.
- 19 MM share float.
- $30 MM market cap
- Electrical construction backlog increased to $77.8 million at February 27, 2012 from $12.2 million at year end.
- Q4 2011: $.06 EPS on $11 million revenue.
- 2012 Forecast: Revenue projected to increase to $55 million. Profits should approach $.30 per share.
-Most successful US Hedge Fund, Renaissance, owns stake.
No brainer alertL GV AMEX + 20%
GV is up 100% this year, but is still trading at a huge discount.
GV announced $.06 EPS in Q4 2011 on $11 million sales.
GV HAS THE POTENTIAL TO EARN $.30 IN 2012 BASED ON $55 MILLION PROJECTED SALES.
The CEO stated that work from other electric utilities will provide a good opportunity for further growth. The prospects for the electrical construction business are brighter today than at any time in recent history.
GV has a tightly held 19 Million float.
In short, GV has all the ingredients to go much higher in a very short time frame.
HIGHLIGHTS:
- Profitable.
- 19 MM share float.
- $30 MM market cap
- Electrical construction backlog increased to $77.8 million at February 27, 2012 from $12.2 million at year end.
- Q4 2011: $.06 EPS on $11 million revenue.
- 2012 Forecast: Revenue projected to increase to $55 million. Profits should approach $.30 per share.
-Most successful Largest US Hedge Fund, Renaissance, owns stake.
GV:AMEX $.70 blowout earnings could double today 6c vs 1c revs +31%, 77.8 million backlog of which $55m to be completed in 2012 which alone almost doubles annual revenues.
.30 - .40 eps this year?
With a 16 PE for the sector could hit $3.
GV:AMEX blowout earnings could double today 6c vs 1c revs +31%, 77.8 million backlog of which $55m to be completed in 2012 which alone almost doubles annual revs.
.30 - .40 eps this year?
With a 16 PE for the sector could hut $3.
New IPAD, HAUP provides streaming
http://finance.yahoo.com/q/hp?s=HAUP+Historical+Prices
HAUP has exploded $1 in one day many times in the past, profitable last quarter.
Live streaming for IPAD
http://www.engadget.com/2011/01/08/hauppauge-debuts-broadway-live-tv-streamer-for-iphones-and-ipads/
New IPAD, HAUP provides streaming
http://finance.yahoo.com/q/hp?s=HAUP+Historical+Prices
HAUP has exploded $1 in one day many times in the past, profitable last quarter.
Live streaming for IPAD
http://www.engadget.com/2011/01/08/hauppauge-debuts-broadway-live-tv-streamer-for-iphones-and-ipads/
Fitness Fanatics: NLS will announce Blowout results Monday
They preannounced $60 million sales for Q4. With costs down about $3 million per quarter and 40% margins, they should report $.15 to $.20 EPS.
Executives just awarded themselves a bunch of options at $2.85. A rich New York couple also just bought 1.5 Million shares.
I think this sees $4 soon.
http://finance.yahoo.com/news/Nautilus-Announces-Strong-bw-2382854812.html?x=0
NLS will announce Blowout results Monday
They preannounced $60 million sales for Q4. With costs down about $3 million per quarter and 40% margins, they should report $.15 to $.20 EPS.
Executives just awarded themselves a bunch of options at $2.85. A rich New York couple also just bought 1.5 Million shares.
I think this sees $4 soon.
http://finance.yahoo.com/news/Nautilus-Announces-Strong-bw-2382854812.html?x=0
NLS will announce Blowout results Monday
Although NLS is more a health stock rather than a biotech, its worth mentioning. They preannounced $60 million sales for Q4. With costs down about $3 million per quarter and 40% margins, they should report $.15 to $.20 EPS.
Executives just awared themselves a bunch of options at $2.85.
I think this sees $4 soon.
http://finance.yahoo.com/news/Nautilus-Announces-Strong-bw-2382854812.html?x=0
Can't believe LCAV, posted at $.2.20
Yes $2 coming this is cheapest Facebook play.